The complexity and diversity of Alzheimer’s disease (AD) make it difficult to diagnose accurately. The use of biomarkers can promote the improvement of the diagnostic effectiveness and sensitivity of AD. Creative BioMart Biomarker is one of the experts who are professional in single biomarker detection. We have years of biomarker detection experience and advanced technology platform to provide fast, sensitive and repeatable AD biomarker detection services according to customer needs.
AD is one of the most common dementias among the elderly in the world. AD has a high prevalence worldwide, with about a million new cases appearing each year. The main symptoms of AD patients include memory loss, cognitive impairment, disorientation and mental symptoms. The initial clinical diagnosis of AD relies on neurological examination, mental state testing and brain imaging. Generally, there are significantly more serious pathological changes in patients with early-onset AD, but the severity of neuropathological changes in individuals with late-onset AD varies greatly between individuals. In older patients, this level of change overlaps with changes in elderly people with impaired cognition, and most patients diagnosed late have no pure plaque and tangle. The unpredictable clinical symptoms of patients with late-onset AD have brought difficulties and challenges to clinical diagnosis. At present, the accuracy of purely clinical diagnosis of AD is low, and the sensitivity and specificity of diagnosis also need to be improved. The correct diagnosis of AD is very important for its treatment and is conducive to the use of symptomatic drugs, such as acetylcholine esterase (AChE) inhibitors and NMDA-receptor antagonists. The development of biomarkers, whether it is blood biomarkers or cerebrospinal fluid biomarkers, is conducive to objectively assess the patient’s physiological status. As effective biomarkers for AD, they help to describe the pathophysiological process of the brain, reflect pharmacological changes, and have sensitivity and specificity. Amyloid beta, tau protein and phosphorylated tau are currently recognized internationally as biomarkers for the diagnosis of AD, increasing the effectiveness of diagnosis. In addition, there are many AD-related biomarkers to be developed.
Figure 1. Schematic diagram of a neuron with intracellular neurofibrillary tangles and extracellular neuritic amyloid plaques (Blennow, et al. 2018)
Creative BioMart Biomarker offers a wide range of AD related biomarker detection based on customer needs. Through advanced instruments, we accept different samples of different concentrations and ensure a wide kinetic range to detect samples of different concentrations. In addition, different biomarkers have different detection effects in different samples, we can customize the detection plan according to customer needs, and obtain the ideal test results with appropriate samples and advanced detection methods.
Creative BioMart Biomarker strictly controls each specific experimental step in the detection procedure to ensure accurately quantify the level of biomarkers related to AD in each sample.
At Creative BioMart Biomarker, we not only provide high-quality AD biomarker detection service, but also provide detection services for other biomarkers. Additionally, our experts can also provide and help design a proper technological scheme according to your specific requirements. Please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.